Hyperfine, Inc. — Q3 2022 Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2022. Hyperfine develops and commercializes the Swoop portable MRI system; all reported revenue to date came from that system and related services. The financial statements combine and consolidate Hyperfine and its subsidiaries.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $2.35 million | $0.37 million | $5.39 million | $1.06 million |
| Gross profit (loss) | $0.69 million | ($0.34 million) | $0.61 million | ($0.71 million) |
| Gross margin | 29.3% | (91.1%) | 11.3% | (67.4%) |
| Operating expenses | $13.97 million | $16.05 million | $60.85 million | $38.07 million |
| Net loss | ($13.17 million) | ($16.39 million) | ($60.11 million) | ($38.77 million) |
| Operating cash flow | Not separately stated for the quarter | Not separately stated for the quarter | ($56.99 million) | ($29.05 million) |
At September 30, 2022, cash and cash equivalents were $132.5 million and restricted cash was $1.3 million. Current assets were $143.7 million against current liabilities of $12.5 million. Total liabilities were $13.3 million; the balance sheet reports no debt. Accumulated deficit was $196.4 million. The company reported no income tax provision.
Changes versus comparable periods
- Q3 revenue increased 533% year over year, driven by higher device sales and installations; nine-month revenue increased 409%. Device revenue was $1.95 million in Q3 and $4.31 million year to date.
- Gross margin moved to positive in both periods, though nine-month gross profit remained modest relative to operating expenses.
- Q3 net loss narrowed 20%, while the nine-month net loss widened 55%, reflecting higher year-to-date operating expenses.
- Operating cash use increased to $57.0 million for the first nine months from $29.0 million a year earlier. Cash, cash equivalents and restricted cash declined $57.4 million during the period.
- The installed base reached 100 systems, versus 50 a year earlier: 57 commercial, 20 grant-funded and 23 research units.
Outlook, management commentary and risks
- Management expects continued significant cash burn and recurring losses while investing in product development and commercialization. It stated existing cash and expected product and service proceeds should fund planned operations for at least the next 12 months; no specific revenue or earnings guidance was provided.
- Management cited plans for commercial and international expansion, continued Swoop development, and early-stage development of Liminal’s brain-sensing platform. It said it would assess strategic options for Liminal.
- COVID-related limits on hospital access and demonstrations affected sales activity, although site access improved in Q3. The company also cited component shortages, longer lead times, and higher materials, labor and transport costs.
- Production depends on a limited supplier base, including Benchmark for Swoop scanners and a single-source European magnet supplier. Loss or disruption of key suppliers could delay deliveries or increase costs.
- The company had two disclosed material weaknesses in internal control over financial reporting; disclosure controls were not effective as of quarter-end. Remediation efforts were underway, with no assurance they would be effective.
- The former CEO resigned effective July 29, 2022. Forfeiture of his unvested awards reversed $4.5 million of previously recognized stock compensation in Q3. A stock-option repricing was effected October 31, 2022, after quarter-end.
- As of the filing, the Class A share price was below Nasdaq’s $1.00 minimum bid-price threshold, creating potential delisting risk if compliance is not regained after any deficiency notice.
- The company reported no material ongoing legal proceedings. A $1.0 million service-provider payment would be due if earn-out shares are issued; the earn-out trigger had not been met and no liability was recorded.
Key facts for investors to verify
- Whether revenue growth and system installations continue, and whether device and service economics sustain positive gross margins.
- Cash-burn trends and the assumptions behind management’s stated minimum 12-month liquidity outlook.
- Supplier capacity, component availability, product costs, and the ability to expand commercialization internationally.
- Progress in remediating internal-control weaknesses and any subsequent Nasdaq listing developments.
- The accounting and potential dilution effects of the October 2022 option repricing and any future earn-out share issuance.